{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:13:49Z","timestamp":1789384429009,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To interrupt residual malaria transmission and achieve successful elimination of <jats:italic>Plasmodium falciparum<\/jats:italic> in low-transmission settings, the World Health Organization (WHO) recommends the administration of a single dose of 0.25\u00a0mg\/kg (or 15\u00a0mg\/kg for adults) primaquine (PQ) combined with artemisinin-based combination therapy (ACT), without glucose-6-phosphate dehydrogenase (G6PD) testing. However, due to the risk of haemolysis in patients with G6PD deficiency (G6PDd), PQ use is uncommon. Thus, this study aimed to assess the safety of a single low dose of PQ administered to patients with G6PD deficiency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An observational cohort study was conducted with patients treated for uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria with either single-dose PQ (0.25\u00a0mg\/kg) (SLD PQ)\u2009+\u2009ACT or ACT alone. Microscopy-confirmed uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria were followed up for 28\u00a0days through clinical and laboratory diagnosis, such as measurements of G6PD levels and haemoglobin (Hb) concentrations. G6PD levels were measured by a quantiative CareSTART\u2122 POCT S1 biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ\u2009+\u2009ACT or ACT alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 249 patients with uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 28\u201315) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT\u2009+\u2009SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT\u2009+\u2009SLD-PQ were reduced by an average of 0.45\u00a0g\/dl (95% CI\u2009=\u20090.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30\u00a0g\/dl (95% CI\u2009=\u20090.14 to \u2212\u00a00.47) in patients treated with ACT alone (<jats:italic>P<\/jats:italic>\u2009=\u20090.157). A greater mean Hb reduction was observed on day 7 in the G6PDd ACT\u2009+\u2009SLD-PQ group (\u2212\u00a00.60\u00a0g\/dL) than in the G6PDd ACT alone group (\u2212\u00a00.48\u00a0g\/dL); however, there was no statistically significant difference (<jats:italic>P<\/jats:italic>\u2009=\u20090.465). Overall, D14 losses were 0.10\u00a0g\/dl (95% CI\u2009=\u2009\u2212\u00a00.00 to 0.20) and 0.05\u00a0g\/dl (95% CI\u2009=\u2009\u2212\u00a00.123 to 0.22) in patients with and without SLD-PQ, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.412).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study\u2019s findings indicate that using SLD-PQ in combination with ACT is safe for uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria regardless of the patient's G6PD status in Ethiopian settings. Caution should be taken in extrapolating this finding in other settings with diverse G6DP phenotypes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-024-05021-x","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T14:02:00Z","timestamp":1720792920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Kassahun","family":"Habtamu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallelujah","family":"Getachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Abossie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assalif","family":"Demissew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arega","family":"Tsegaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teshome","family":"Degefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chieh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofa","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Kibret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Kazura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyene","family":"Petros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delenasaw","family":"Yewhalaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"5021_CR1","doi-asserted-by":"crossref","unstructured":"Pousibet-Puerto J, Salas-Coronas J, S\u00e1nchez-Crespo A, Molina-Arrebola MA, Soriano-P\u00e9rez MJ, Gim\u00e9nez-L\u00f3pez MJ, et al. Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone. Malar J; 2016;15:339.","DOI":"10.1186\/s12936-016-1408-1"},{"key":"5021_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","volume":"14","author":"WWARN Gametocyte Study Group","year":"2016","unstructured":"WWARN Gametocyte Study Group. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;14:79.","journal-title":"BMC Med"},{"key":"5021_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","volume":"14","author":"BP Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves BP, Tiono AB, Ou\u00e9draogo A, Guelb\u00e9ogo WM, Bradley J, Nebie I, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med. 2016;14:40.","journal-title":"BMC Med"},{"key":"5021_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12936-018-2373-7","volume":"17","author":"JM Roth","year":"2018","unstructured":"Roth JM, Sawa P, Omweri G, Osoti V, Makio N, Bradley J, et al. Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment. Malar J. 2018;17:223.","journal-title":"Malar J"},{"key":"5021_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/parasitologia2020011","volume":"2","author":"BA Munro","year":"2022","unstructured":"Munro BA, McMorran BJ. Antimalarial drug strategies to target Plasmodium gametocytes. Parasitologia. 2022;2:101\u201324.","journal-title":"Parasitologia"},{"key":"5021_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/cix355","volume":"65","author":"RC Tine","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"5021_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","volume":"13","author":"NJ White","year":"2013","unstructured":"White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175\u201381.","journal-title":"Lancet Infect Dis"},{"key":"5021_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12916-017-0990-6","volume":"16","author":"WR Taylor","year":"2018","unstructured":"Taylor WR, Naw HK, Maitland K, Williams TN, Kapulu M, D\u2019Alessandro U, et al. Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria\u2013a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Med. 2018;16:11.","journal-title":"BMC Med"},{"key":"5021_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12916-022-02504-z","volume":"20","author":"K Stepniewska","year":"2022","unstructured":"Stepniewska K, Allen EN, Humphreys GS, Poirot E, Craig E, Kennon K, Yilma D, et al. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. BMC Med. 2022;20:350.","journal-title":"BMC Med"},{"key":"5021_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S1473-3099(15)00479-X","volume":"16","author":"A Dicko","year":"2016","unstructured":"Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis. 2016;16:674\u201384.","journal-title":"Lancet Infect Dis"},{"key":"5021_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s15010-022-01905-9","volume":"51","author":"H Liu","year":"2023","unstructured":"Liu H, Zeng W, Malla P, Wang C, Lakshmi S, Kim K, et al. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. Infection. 2023;51:213\u201322.","journal-title":"Infection"},{"key":"5021_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12936-018-2564-2","volume":"17","author":"S Avalos","year":"2018","unstructured":"Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, et al. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients. Malar J. 2018;17:415.","journal-title":"Malar J"},{"key":"5021_CR13","unstructured":"WHO. Guidelines for Malaria, 16 February 2021. Geneva, World Health Organization; 2021."},{"key":"5021_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12: e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"5021_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12936-018-2248-y","volume":"17","author":"CS Chu","year":"2018","unstructured":"Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malar J. 2018;17:101.","journal-title":"Malar J"},{"key":"5021_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","volume":"81","author":"RE Howes","year":"2013","unstructured":"Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133\u2013201.","journal-title":"Adv Parasitol"},{"key":"5021_CR17","doi-asserted-by":"publisher","first-page":"17106","DOI":"10.1038\/s41598-020-74200-y","volume":"10","author":"Y He","year":"2020","unstructured":"He Y, Zhang Y, Chen X, Wang Q, Ling L, Xu Y. Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population: molecular characterization and genotype\u2013phenotype association throughout an activity distribution. Sci Rep. 2020;10:17106.","journal-title":"Sci Rep"},{"key":"5021_CR18","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41598-021-82477-w","volume":"11","author":"S Sathupak","year":"2021","unstructured":"Sathupak S, Leecharoenkiat K, Kampuansai J. Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Lue ethnic group of northern Thailand. Sci Rep. 2021;11:2956.","journal-title":"Sci Rep"},{"key":"5021_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12936-018-2271-z","volume":"17","author":"SS Awandu","year":"2018","unstructured":"Awandu SS, Raman J, Makhanthisa TI, Kruger P, Frean J, Bousema T, et al. Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa. Malar J. 2018;17:120.","journal-title":"Malar J"},{"key":"5021_CR20","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/infdis\/jiy014","volume":"217","author":"I Chen","year":"2018","unstructured":"Chen I, Diawara H, Mahamar A, Sanogo K, Keita S, Kone D, et al. Safety of single-dose primaquine in G6PD-deficient and G6PD-normal males in Mali without malaria: an open-label, phase 1, dose-adjustment trial. J Infect Dis. 2018;217:1298\u2013308.","journal-title":"J Infect Dis"},{"key":"5021_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"5021_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12879-019-3862-1","volume":"19","author":"L Dysoley","year":"2019","unstructured":"Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S, et al. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019;19:250.","journal-title":"BMC Infect Dis"},{"key":"5021_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"key":"5021_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12936-022-04100-1","volume":"21","author":"RO Mwaiswelo","year":"2022","unstructured":"Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, M\u00e5rtensson A. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district. Tanzania Malar J. 2022;21:84.","journal-title":"Tanzania Malar J"},{"key":"5021_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12936-016-1410-7","volume":"15","author":"E Poirot","year":"2016","unstructured":"Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, et al. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15:384.","journal-title":"Malar J"},{"key":"5021_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190272","volume":"13","author":"GJ Bastiaens","year":"2018","unstructured":"Bastiaens GJ, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Goncalves BP, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials. PLoS ONE. 2018;13: e0190272.","journal-title":"PLoS ONE"},{"key":"5021_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S1473-3099(22)00658-2","volume":"23","author":"WR Taylor","year":"2023","unstructured":"Taylor WR, Olupot-Olupot P, Onyamboko MA, Peerawaranun P, Weere W, Namayanja C, et al. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet Infect Dis. 2023;23:471\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5021_CR28","unstructured":"WHO. Evidence review group: the safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. Bangkok, Thailand 2012:13\u201315."},{"key":"5021_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s13071-021-05034-4","volume":"14","author":"SW van Beek","year":"2021","unstructured":"van Beek SW, Svensson EM, Tiono AB, Okebe J, D\u2019Alessandro U, Gon\u00e7alves BP, et al. Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. Parasit Vectors. 2021;14:524.","journal-title":"Parasit Vectors"},{"key":"5021_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001023","volume":"2","author":"S Shekalaghe","year":"2007","unstructured":"Shekalaghe S, Drakeley C, Gosling R, Ndaro A, Van Meegeren M, Enevold A, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS ONE. 2007;2: e1023.","journal-title":"PLoS ONE"},{"key":"5021_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/infdis\/jiaa498","volume":"225","author":"K Stepniewska","year":"2022","unstructured":"Stepniewska K, Humphreys GS, Gon\u00e7alves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J Infect Dis. 2022;225:1215\u201326.","journal-title":"J Infect Dis"},{"key":"5021_CR32","doi-asserted-by":"crossref","unstructured":"Mukaka M, Onyamboko MA, Olupot-Olupot P, Peerawaranun P, Suwannasin K, Pagornrat W, et al. Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria. eBioMedicine. 2023;96:104805.","DOI":"10.1016\/j.ebiom.2023.104805"},{"key":"5021_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","volume":"18","author":"A Dicko","year":"2018","unstructured":"Dicko A, Roh ME, Diawara H, Mahamar A, Soumare HM, Lanke K, et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Lancet Infect Dis. 2018;18:627\u201339.","journal-title":"Lancet Infect Dis"},{"key":"5021_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12936-020-03416-0","volume":"19","author":"A Demissew","year":"2020","unstructured":"Demissew A, Hawaria D, Kibret S, Animut A, Tsegaye A, Lee MC, et al. Impact of sugarcane irrigation on malaria vector Anopheles mosquito fauna, abundance and seasonality in Arjo-Didessa. Ethiopia Malar J. 2020;19:344.","journal-title":"Ethiopia Malar J"},{"key":"5021_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12936-023-04782-1","volume":"22","author":"A Tsegaye","year":"2023","unstructured":"Tsegaye A, Demissew A, Hawaria D, Abossie A, Getachew H, Habtamu K, et al. Anopheles larval habitats seasonality and environmental factors affecting larval abundance and distribution in Arjo-Didessa sugar cane plantation. Ethiopia Malar J. 2023;22:350.","journal-title":"Ethiopia Malar J"},{"key":"5021_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12936-023-04762-5","volume":"22","author":"H Getachew","year":"2023","unstructured":"Getachew H, Demissew A, Abossie A, Habtamu K, Wang X, Zhong D, et al. Asymptomatic and submicroscopic malaria infections in sugar cane and rice development areas of Ethiopia. Malar J. 2023;22:341.","journal-title":"Malar J"},{"key":"5021_CR37","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization; 2015."},{"key":"5021_CR38","unstructured":"WHO. Guidelines for malaria. Geneva, World Health Organization; 2023."},{"key":"5021_CR39","unstructured":"Ethiopia FMoH. National malaria guidelines. Addis Ababa, 2018."},{"key":"5021_CR40","unstructured":"WHO. Giemsa staining of malaria blood films. Geneva, World Health Organization; 2016."},{"key":"5021_CR41","unstructured":"WHO. Basic malaria microscopy. Geneva, World Health Organization; 2010."},{"key":"5021_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1475-2875-12-391","volume":"12","author":"GJ Domingo","year":"2013","unstructured":"Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.","journal-title":"Malar J"},{"key":"5021_CR43","first-page":"260","volume":"21","author":"TT Shenkutie","year":"2022","unstructured":"Shenkutie TT, Nega D, Hailu A, Kepple D, Witherspoon L, Lo E, et al. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre. Eastern Ethiopia Malar J. 2022;21:260.","journal-title":"Eastern Ethiopia Malar J"},{"key":"5021_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12936-019-2981-x","volume":"18","author":"E Lo","year":"2019","unstructured":"Lo E, Zhong D, Raya B, Pestana K, Koepfli C, Lee M-C, et al. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. Malar J. 2019;18:340.","journal-title":"Malar J"},{"key":"5021_CR45","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/diagnostics13243647","volume":"13","author":"V Leung-Pineda","year":"2023","unstructured":"Leung-Pineda V, Weinzierl EP, Rogers BB. Preliminary investigation into the prevalence of G6PD deficiency in a pediatric African American population using a near-patient diagnostic platform. Diagnostics. 2023;13:3647.","journal-title":"Diagnostics"},{"key":"5021_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/inthealth\/ihy060","volume":"11","author":"GJ Domingo","year":"2019","unstructured":"Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, et al. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. Int Health. 2019;11:7\u201314.","journal-title":"Int Health"},{"key":"5021_CR47","doi-asserted-by":"crossref","unstructured":"Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P. falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet. 2023;402:2101\u201310.","DOI":"10.1016\/S0140-6736(23)01553-2"},{"key":"5021_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-020-3121-3","volume":"19","author":"S Shekalaghe","year":"2020","unstructured":"Shekalaghe S, Mosha D, Hamad A, Mbaga TA, Mihayo M, Bousema T, et al. Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether\u2013lumefantrine. Malar J. 2020;19:34.","journal-title":"Malar J"},{"key":"5021_CR49","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiz313","volume":"220","author":"WR Taylor","year":"2019","unstructured":"Taylor WR, Kheng S, Muth S, Tor P, Kim S, Bjorge S, et al. Hemolytic dynamics of weekly primaquine antirelapse therapy among Cambodians with acute Plasmodium vivax malaria with or without glucose-6-phosphate dehydrogenase deficiency. J Infect Dis. 2019;220:1750\u201360.","journal-title":"J Infect Dis"},{"key":"5021_CR50","doi-asserted-by":"publisher","first-page":"1640480","DOI":"10.1155\/2020\/1640480","volume":"2020","author":"R Kyeremeh","year":"2020","unstructured":"Kyeremeh R, Antwi-Baffour S, Annani-Akollor M, Adjei JK, Addai-Mensah O, Frempong M. Comediation of erythrocyte haemolysis by erythrocyte-derived microparticles and complement during malaria infection. Adv Hematol. 2020;2020:1640480.","journal-title":"Adv Hematol"},{"key":"5021_CR51","doi-asserted-by":"crossref","unstructured":"Mosha D, Kakolwa MA, Mahende MK, Masanja H, Abdulla S, Drakeley C, et al. Safety monitoring experience of single-low dose primaquine co-administered with artemether\u2013lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania. Malar J. 20:392.","DOI":"10.1186\/s12936-021-03921-w"},{"key":"5021_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"},{"key":"5021_CR53","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.2021015055","volume":"139","author":"NJ White","year":"2022","unstructured":"White NJ. What causes malaria anemia? Blood. 2022;139:2268\u20139.","journal-title":"Blood"},{"key":"5021_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12936-023-04493-7","volume":"22","author":"EJ Nelwan","year":"2023","unstructured":"Nelwan EJ, Shakinah S, Pasaribu A. Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis. Malar J. 2023;22:77.","journal-title":"Malar J"},{"key":"5021_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41182-022-00408-5","volume":"50","author":"RO Mwaiswelo","year":"2022","unstructured":"Mwaiswelo RO, Kabuga H, Kweka EJ, Baraka V. Is it time for Africa to adopt primaquine in the era of malaria control and elimination? Trop Med Health. 2022;50:17.","journal-title":"Trop Med Health"},{"key":"5021_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12936-017-1989-3","volume":"16","author":"OA Uthman","year":"2017","unstructured":"Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malar J. 2017;16:346.","journal-title":"Malar J"},{"key":"5021_CR57","doi-asserted-by":"crossref","unstructured":"Barcellini W, Fattizzo B: Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers 2015, 2015.","DOI":"10.1155\/2015\/635670"},{"key":"5021_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1473-3099(18)30070-7","volume":"18","author":"RN Price","year":"2018","unstructured":"Price RN, White NJ. Drugs that reduce transmission of falciparum malaria. Lancet Infect Dis. 2018;18:585\u20136.","journal-title":"Lancet Infect Dis"},{"key":"5021_CR59","doi-asserted-by":"crossref","unstructured":"Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, et al. Single low dose primaquine (0.25 mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS One 2016;11:e0151898.","DOI":"10.1371\/journal.pone.0151898"},{"key":"5021_CR60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tox.2012.01.015","volume":"294","author":"S Ganesan","year":"2012","unstructured":"Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology. 2012;294:54\u201360.","journal-title":"Toxicology"},{"key":"5021_CR61","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood.2019000944","volume":"136","author":"L Luzzatto","year":"2020","unstructured":"Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136:1225\u201340.","journal-title":"Blood"},{"key":"5021_CR62","unstructured":"WHO. Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva, World Health Organization; 2015."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05021-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T14:02:54Z","timestamp":1720792974000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05021-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5021"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05021-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at the University of Addis Ababa's Natural & Computational Sciences (IRB) (CNSDO\/20 1 111\/2018). There were no unanticipated problems involving risks to volunteers or others, and no significant deviations were noted. Before the study was screened, all willing participants older than eighteen years were asked to provide written informed consent; for those younger, approval was obtained from parents or legal guardians. A witness who could read was utilized for patients who could not provide their consent, and children's consent was also sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}